Bryce Point Capital LLC Invests $543,000 in Cencora, Inc. (NYSE:COR)

Bryce Point Capital LLC bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,415 shares of the company's stock, valued at approximately $543,000.

Several other large investors also recently modified their holdings of the business. JFS Wealth Advisors LLC grew its position in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Cencora in the fourth quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. Kentucky Trust Co bought a new position in Cencora in the 4th quarter worth $33,000. Finally, WASHINGTON TRUST Co lifted its position in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. This represents a 21.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares of the company's stock, valued at $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock valued at $8,034,778 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Down 0.3 %

Shares of NYSE COR traded down $0.86 during midday trading on Wednesday, reaching $273.87. 4,241,472 shares of the company's stock traded hands, compared to its average volume of 1,497,578. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $53.11 billion, a price-to-earnings ratio of 38.96, a P/E/G ratio of 1.31 and a beta of 0.55. The stock's 50 day simple moving average is $259.12 and its 200-day simple moving average is $244.21. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Analyst Ratings Changes

COR has been the subject of a number of research reports. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.